Esomeprazole for Treatment of GERD in Pediatric Patients
Public ClinicalTrials.gov record NCT00228527. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Multicentre, Randomized, Double-blind Parallel-group Study to Evaluate the Safety and Clinical Outcome of Once Daily Esomeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients 1 to 11 Years of Age, Inclusive.
Study identification
- NCT ID
- NCT00228527
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 100 participants
Conditions and interventions
Interventions
- Esomeprazole (Nexium) Drug
Drug
Eligibility (public fields only)
- Age range
- 1 Year to 11 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2004
- Primary completion
- Not listed
- Completion
- Sep 30, 2005
- Last update posted
- Nov 18, 2010
2004 – 2005
United States locations
- U.S. sites
- 24
- U.S. states
- 18
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Mobile | Alabama | — | — |
| Research Site | Phoenix | Arizona | — | — |
| Research Site | Wilmington | Delaware | — | — |
| Research Site | Orlando | Florida | — | — |
| Research Site | Chicago | Illinois | — | — |
| Research Site | Park Ridge | Illinois | — | — |
| Research Site | Boston | Massachusetts | — | — |
| Research Site | Detroit | Michigan | — | — |
| Research Site | Troy | Michigan | — | — |
| Research Site | Jackson | Mississippi | — | — |
| Research Site | St Louis | Missouri | — | — |
| Research Site | Omaha | Nebraska | — | — |
| Research Site | Morristown | New Jersey | — | — |
| Research Site | Brooklyn | New York | — | — |
| Research Site | Buffalo | New York | — | — |
| Research Site | West Islip | New York | — | — |
| Research Site | Columbus | Ohio | — | — |
| Research Site | Hershey | Pennsylvania | — | — |
| Research Site | Philadelphia | Pennsylvania | — | — |
| Research Site | Chattanooga | Tennessee | — | — |
| Research Site | Dallas | Texas | — | — |
| Research Site | Houston | Texas | — | — |
| Research Site | Burlington | Vermont | — | — |
| Research Site | Norfolk | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00228527, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 18, 2010 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00228527 live on ClinicalTrials.gov.